Please login to the form below
Enterprise Therapeutics appoints CEO
Dr John Ford will lead the UK drug discovery company
Brighton, UK-based respiratory diseases specialist Enterprise Therapeutics has appointed Dr John Ford as chief executive officer, with immediate effect.
In his new role, Dr Ford will oversee the development of the company's novel muco-regulatory therapies for patients suffering with chronic obstructive pulmonary disease, cystic fibrosis and severe asthma.
He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002.
Dr Ford also brings experience from Ario Pharma, where he is currently chief executive officer and co-founder, and Metrion Biosciences, where he serves as co-owner and investor director.
Previously, Dr Ford has worked as general manager of Akarna Therapeutics' UK operations, chief operating officer of Dezima Pharma and a team leader for cell-based drug discovery campaigns at BioFocus Discovery.
Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels, drug development, and biotech fundraising position him uniquely to lead Enterprise Therapeutics moving forward.
“His expertise will complement the existing team and we are thrilled to have him on board.”
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Account Director
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Senior Account Manager
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Nucleus Global announces a trio of promotions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Pfizer introduces new logo in a ‘shift from commerce to science’
- PHE study finds people who have had COVID-19 can still transmit the virus
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- New study identifies drugs that are safe to use in COVID-19 treatment
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Bedrock Group
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
